# TRAP (nephropathy) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/nephropathy

> TRAP (nephropathy), sponsored by Biohaven Ltd. (BHVN): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TRAP (nephropathy) |
| Codes | BHV-1400 |
| Sponsor | Biohaven Ltd. (BHVN) https://sec-api.dev/companies/bhvn/catalysts |
| Indications | igan, and plan to initiate a pivotal trial in 2026 using urine protein-creatinine ratio |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Q4 2024: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2024-11-12, last confirmed 2024-11-12.
- SEC Form 10-Q (accession 0001935979-24-000085): "We expect to initiate Phase 1 studies of BHV-1400 in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1935979/000193597924000085/bhvn-20240930.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: IgAN, and plan to initiate a pivotal trial in 2026 using urine protein-creatinine ratio.
- First seen 2025-08-11, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001935979-26-000093): "•On track to initiate the pivotal Phase 3 trial of BHV-1400, a TRAP™ extracellular degrader targeting galactose-deficient IgA1 (Gd-IgA1), in IgA nephropathy (IgAN) during 4Q 2026." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000093/a2026q3bhvnearningsprex991.htm
- SEC Form 10-Q (accession 0001935979-26-000045): "BHV-1400 has been dosed in a clinically concluded phase 1 study in normal healthy volunteers and continues to be dosed in an expansion cohort of IgAN patients with plans to initiate the pivotal study in IgAN patients by mid-year 2026." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000045/bhvn-20260331.htm
- SEC Form 10-K (accession 0001935979-26-000020): "BHV-1400 has been dosed in a clinically concluded phase 1 study in normal healthy volunteers and continues to be dosed in an expansion cohort of IgAN patients with plans to initiate the pivotal study in IgAN patients in 2026." https://www.sec.gov/Archives/edgar/data/1935979/000193597926000020/bhvn-20251231.htm
- SEC Form 10-Q (accession 0001935979-25-000068): "Based upon the rapid and deep reductions of Gd-IgA1 observed with SC BHV-1400, we have expanded our Phase 1 study of BHV-1400 in patients with IgAN, and plan to initiate a pivotal trial in 2026 using urine protein-creatinine ratio as a surrogate endpoint for accelerated approval." https://www.sec.gov/Archives/edgar/data/1935979/000193597925000068/bhvn-20250630.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/nephropathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TRAP (nephropathy) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/nephropathy

```bibtex
@misc{secapidev_pdufa_nephropathy_20261116,
  title        = {TRAP (nephropathy) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/nephropathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_nephropathy_20261116","title":"TRAP (nephropathy) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/nephropathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
